Heart failure with preserved ejection fraction (HFpEF) is characterized by signs and symptoms of heart failure in the presence of a normal left ventricular ejection fraction. Despite accounting for up to 50% of all clinical presentations of heart failure, the mechanisms implicated in HFpEF are poorly understood, thus precluding effective therapy. The pathophysiological heterogeneity in the HFpEF phenotype also contributes to this disease and likely to the absence of evidence-based therapies. Limited access to human samples and imperfect animal models that completely recapitulate the human HFpEF phenotype have impeded our understanding of the mechanistic underpinnings that exist in this disease. Aging and comorbidities such as atrial fibrillation, hypertension, diabetes and obesity, pulmonary hypertension, and renal dysfunction are highly associated with HFpEF, yet the relationship and contribution between them remains ill-defined. This review discusses some of the distinctive clinical features of HFpEF in association with these comorbidities and highlights the advantages and disadvantage of commonly used murine models used to study the HFpEF phenotype. reported that he has no relationships relevant to the content of this paper to report.
HFrEF can be regarded as a cardiac-centric syndrome driven by myocardial cell loss and dysfunction with the heart being subjected to higher wall stress as
shown by elevated levels of brain natriuretic peptide (BNP). HFpEF, alternatively, is a systemic syndrome characterized by accumulated risk factors and comorbidities and a noncompliant and stiff heart that is exposed to lower wall stress, reflected in lower BNP levels that, although elevated, are not as high as in
HFrEF (6-8). Therefore, it appears that HFrEF begins from the heart and leads to peripheral changes, whereas HFpEF starts in the periphery and culminates at the heart (4,9).
SPEAKING THE SAME LANGUAGE: THE CHALLENGE FOR TRANSLATIONAL HFpEF
RESEARCHERS. Semantics related to HFpEF are a formidable task for translational researchers. Defining various terms, and therefore collecting relevant data, remains a challenge both clinically and in the preclinical area. One of the main sources of confusion lies in the distinction between diastolic dysfunction and HFpEF. These 2 terms have been used interchangeably in both the preclinical and the clinical literature. Diastolic dysfunction was widely and incorrectly touted to be the sine qua non for HFpEF but by itself is not enough to establish it.
For example, normal subjects may have diastolic dysfunction, yet have no clinical features of HFpEF (10,11). Additionally, diastolic dysfunction is a common occurrence in HFrEF (12). Also, use of strain imaging with echocardiography shows subtle abnormalities in systolic function in some HFpEF populations despite preserved global LVEF (13, 14) .
According to the 2013 American College of Cardiology
Foundation (ACCF)/American Heart Association (AHA) guideline for the management of HF (3), neither LV hypertrophy nor diastolic dysfunction is required for diagnosis of HFpEF, whereas in the European HF guidelines relevant structural and/or diastolic dysfunction is a prerequisite (2). HFpEF is also a term, in the sphere of scientific literature, that is virtually nonexistent, given that the U.S. National Library of Medicine's system of medical subject headings (MeSH) still uses the outmoded terms "HF, systolic"
and "HF, diastolic" to index publications. Hence, we prefer the terms HFpEF and HFrEF as they are mutually exclusive, whereas diastolic dysfunction may be present in either systolic HF (HFrEF) or diastolic HF (HFpEF). However, we acknowledge that until universally agreed definitions are adopted, translational research in the field may be hindered.
MODELING HFpEF IN THE LAB:
DIFFERENT PHENOTYPES FOR
A COMPLEX DISEASE
Animal models, as opposed to isolated organ and/or cell preparations, allow examination of physiological effects of cardiac function (15) . However, the search for an animal model that resembles the human HFpEF phenotype is akin to "a fishing expedition" and the (16, 17) . Moreover, if defining HFpEF in humans evokes controversy (18) , it appears that animal models likely follow suit. Animals, unlike humans, cannot report symptoms. LVEF, diastolic dysfunction, and heart structure can be measured directly, but signs must be inferred from animal behavior. Additionally, separate from LVEF, a single measure of systolic function, there are other measures of LV systolic function such as myocardial velocities, strain, and strain rate (measures of myocardial contractility), which may be impaired in HFpEF (13, 14, 19 (21) . However, similar to humans, a "onesize-fits-all" strategy is unlikely to work in animal models. That being said, the relative importance of comorbidities on the initiation, development, and treatment of HFpEF is unknown (22) . A more tailored approach focusing on specific phenotypes is needed in the laboratory to understand the complex interactions underlying this disease. HFpEF in humans heart failure rat
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D E C E M B E R 2 0 1 7 : 7 7 0 -8 9 is strongly associated with diseases such as hypertension, obesity, and diabetes mellitus (3,6), which by themselves often occur together as part of the metabolic syndrome. Yet there is much overlap between these comorbidities, and a direct causal relationship between one and the other and HFpEF has not been established. However, if such a causal relationship can be elucidated, a step toward developing targeted therapies might be in sight. A major benefit of an animal model is that it is easier to examine the contribution of each risk factor in isolation without additional comorbidities confounding the findings.
Animal models are useful to understand the effect of interventions on the disease process, which in turn helps in the development of therapeutic approaches.
Murine models are convenient and inexpensive, particularly in the quest to investigate the molecular basis underlying HFpEF. This is due to the availability of genetically engineered strains and molecular techniques to manipulate sub cellular processes occurring in the heart, as well as the relatively short life span of murine versus larger animal models (23, 24) . It is important to stress that although murine models offer easy access to genetic manipulations, extensive characterization of the actual HFpEF phenotype is required to be fully useful for HFpEF studies (25) . This being said, specific genetic manipulations may be useful for the development of therapeutics by investigating the specific role of a molecule/factor in the HFpEF syndrome. However, in contrast, specific genetic manipulations that manifest a purported HFpEF phenotype are of little use in understanding common forms of HFpEF or as a disease model.
In this review, we consider whether some of the available murine models of cardiac hypertrophy and HF recapitulate human HFpEF disease. Attention has been paid to those phenotypical characteristics that would characterize an "ideal" HFpEF animal model, which are included in Figure 1 . Although diastolic dysfunction is certainly part of the compendium of the HFpEF phenotype, it is only 1 piece of the puzzle.
It is also necessary to identify models with systemic alterations that are implicated in human HFpEF.
These include impairments in peripheral function, such as exercise intolerance, alterations in pulmonary Mice and rats are commonly used to study aging and age-related diseases (30) . Their relatively short life span makes them easier and more cost-effective to study than long-lived animals. Cardiac aging in murine recapitulates many changes observed in humans, with age-dependent increases in LV (191, (195) (196) (197) 200, 203, 204, 207, 208, 212, 213) 
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Concentric hypertrophy reported from large controlled trials, epidemiological studies, and HF registries (3). Elevated blood pressure is a major determinant of LV structural alterations. Murine models of hypertensive HFpEF have many of the features of human HFpEF, as shown in Table 2 .
There are a wide range of models, and most mimic some aspects of the relevant human HFpEF disease, but no single model recapitulates all, although some more than others. A major deficiency in these models is that they do not reproduce the slow onset seen in patients with hypertension that lead to HFpEF development (62).
Aldosterone-infused and unilateral nephrectomized mouse.
Pioneering studies more than 2 decades ago reported that the combination of uninephrectomy, aldosterone infusion, and 1% sodium chloride (NaCl) administration in rats induced blood pressure elevation, cardiac hypertrophy, and fibrosis (63) (64) (65) . This effect was also described in mice (66) . Circulating aldosterone levels in this HFpEF model are w6.0 to 7.5 ng/ml (67, 68) , Table 1 .
Murine Models of HFpEF (95) (96) (97) Valero-Muñoz et al. 
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Murine Models of HFpEF increased adiposity in HFpEF. (176, 179, 180) . There is also cardiac fibrosis (181) and increased arterial stiffness due to a destabilized elastic fiber network and increased elastolytic activity (182) . Natriuretic peptide cardiac expression is reportedly unchanged or slightly reduced compared with control ob/þ mice (178, 181, 183, 184) . Moreover, although ob/ob mice are less active than their control, this is attributed to excess body weight rather than to their cardiac phenotype (185) . Survival is decreased in ob/ob mice compared with ob/þ mice (186) , and it appears that they die before cardiac hypertrophy 
S t r e p t o z o t o c i n -i n d u c e d d i a b e t i c r a t . Streptozo-
tocin administration in rats was first described in 1963 (189) . Rapid b-cell degranulation and necrosis occurs Tables 1 and 2 .
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7 to 10 h after injection, and causes hyperinsulinemia and hypoglycemia. After longer periods (28 days), prolonged hyperglycemia and a reduction in pancreatic insulin levels ensues (190) . Streptozotocin induces either type 1 or type 2 diabetes, depending on the dosage and duration of administration. Doses of 50 to 65 mg/kg lead to hyperglycemia without ketosis, and insulin administration is not required. However, at higher doses (75 mg/kg and greater) spontaneous ketosis and death occurs within days if insulin is not administered (191) . Streptozotocin-injected rats exhibit many of the cardiovascular complications found in humans with both type 1 and type 2 diabetes.
They have increased levels of cardiac and circulating natriuretic peptides (192, 193) and inflammatory markers, such as interleukin 1, interleukin 6, and intracellular adhesion molecule 1 (194) . Blood pressure remains within normal ranges, indicating that hyperglycemia alone may be sufficient to account for the observed changes seen in the heart in this model (17) . This includes eccentric cardiac hypertrophy, gradual diastolic dysfunction with impaired contractile performance, and increased ventricular stiffness (191, (195) (196) (197) . Fibrosis and a titin-isoform pattern switch is observed (198) (199) (200) , correlating with increased ventricular stiffness (201) . Streptozotocininduced diabetic rats also show altered systolic load of the left ventricle coupled to the arterial system and decreased systemic arterial compliance (202) .
Although relative lung weights are reported to be increased (203) , this is more likely due to a decrease in body weight than to the presence of lung congestion per se, as other studies showed no differences in lung weights relative to tibia length or wet-to-dry lung ratio (204, 205) . Cardiac atrophy is also described, with chronic apoptotic cardiomyocyte loss and inadequate reactive hypertrophy (206) (207) (208) .
There is also significantly reduced cardiac capillary density (209) . whereas others show a reduction in LVEF during diabetes development (214) . This discrepancy could be due to the severity of diabetes or the methods used to evaluate cardiac function (215) .
Z u c k e r r a t . In 1961, a mutation designated "fatty" appeared spontaneously in a group of outbred rats giving rise to the Zucker fatty rat model (216) . This mutation occurs at the leptin receptor gene, resulting in decreased affinity of leptin for its receptor and, consequently, causing hyperphagia and obesity (217) .
These fatty rats, although insulin resistant, did not become diabetic, but later inbreeding using obese and diabetic Zucker rats resulted in the Zucker diabetic fatty rat model (218) . Both these models develop mild hypertension and cardiac alterations such as LV hypertrophy and early diastolic and moderated systolic dysfunction (17, (219) (220) (221) (222) , with preserved LVEF (223) .
There is also cardiomyocyte hypertrophy, vascular rarefaction, and fibrosis (220, (222) (223) (224) . However, to our knowledge, lung congestion or other signs of HFpEF have not been described.
Z u c k e r f a t t y a n d s p o n t a n e o u s l y h y p e r t e n s chronic kidney disease, which may be argued to Historically, cardiac arrhythmias were studied in large mammals such as the goat, pig, or dog, because their hearts were more akin to the human heart than rabbits or rodents (25) . Early studies in dogs (238, 239) showed that the severity of cardiac dysfunction caused by atrial pacing directly correlates with the rate of pacing. This induces an end-stage dilated cardiomyopathy and an HFrEF phenotype, with a significant decrease in both systolic and diastolic function. There was no increase in LV mass nor collagen content (21) .
Although it was believed that arrhythmias did not occur in mice due to their lack of critical cardiac mass (240) , this has been shown to be incorrect (241) . Hypoxia-induced pulmonary hypertensive rat and mouse.
Chronic hypoxia is observed in chronic obstructive pulmonary disease, interstitial lung disease, sleep apnea, and exposure to high altitudes in humans and is thought to play a crucial role in the development of pulmonary hypertension and severe HF (252, 255) .
Similarly, in the research laboratory, chronic hypoxia also leads to pulmonary hypertension (255) . Typically, it is induced by placing the rodent in a hypobaric chamber (either 10% fraction of inspired oxygen or hypobaric pressure of 380 mm Hg, which is equivalent to one-half that at sea level) for 3 to 4 weeks (256) (257) (258) (259) . This model is useful because it is However, to our knowledge, it has not been used as a model of HFpEF associated renal disease and its significance in modeling HFpEF is unknown.
MURINE MODELS: A FUNHOUSE MIRROR?
Relevant preclinical models for HFpEF will provide mechanistic information to understand the contribution of comorbidities that are highly associated with this disease. Additionally, these models will provide insights into pathways relevant to disease development, progression, and potential implications human HFpEF is generally thought to develop progressively over months to years (23) . Moreover, substantial differences exist between rodents and human cardiac features, such as its small size and higher heart rates, which sometimes limit diastolic function measurements, especially when noninvasive techniques, such as echocardiography, are used (103, 283) .
It should also, be emphasized that many murine models of purported HFpEF progress to HFrEF within a variable amount of time, suggesting that in these models, HFpEF is a merely a temporary step to the development to HFrEF, which is rare in human HFpEF (100,103).
The use of murine models is an extremely valuable tool in understanding the pathophysiology of HFpEF.
These models are essential for understanding the molecular alterations underlying the development of the disease, as they allow the identification of molecular pathways that may be causative or contribute to the pathophysiology and progression of HFpEF (23, 103) . However, it is essential for these congestion, which could be assessed by examining either the ratio of lung weight to tibia length or the wet-to-dry lung ratio (17) .
As with all fishing expeditions, we attempt to gather facts about HFpEF using relevant preclinical models that accurately recapitulate the complexities of human HFpEF disease and define specific phenotypes to discover novel targets, ultimately for the development of effective therapeutics (Central Illustration). Valero-Muñoz et al. Murine Models of HFpEF D E C E M B E R 2 0 1 7 : 7 7 0 -8 9
